- Home
- TEI vs FULC Comparison
TEI vs FULC Comparison
Compare TEI & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEI
- FULC
- Stock Information
- Founded
- TEI 1993
- FULC 2015
- Country
- TEI United States
- FULC United States
- Employees
- TEI N/A
- FULC N/A
- Industry
- TEI Finance Companies
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- TEI Finance
- FULC Health Care
- Exchange
- TEI Nasdaq
- FULC Nasdaq
- Market Cap
- TEI 242.3M
- FULC 221.5M
- IPO Year
- TEI N/A
- FULC 2019
- Fundamental
- Price
- TEI $5.22
- FULC $3.96
- Analyst Decision
- TEI
- FULC Hold
- Analyst Count
- TEI 0
- FULC 10
- Target Price
- TEI N/A
- FULC $7.44
- AVG Volume (30 Days)
- TEI 142.4K
- FULC 1.0M
- Earning Date
- TEI 01-01-0001
- FULC 02-25-2025
- Dividend Yield
- TEI 10.51%
- FULC N/A
- EPS Growth
- TEI N/A
- FULC N/A
- EPS
- TEI N/A
- FULC N/A
- Revenue
- TEI N/A
- FULC $80,871,000.00
- Revenue This Year
- TEI N/A
- FULC $2,821.96
- Revenue Next Year
- TEI N/A
- FULC N/A
- P/E Ratio
- TEI N/A
- FULC N/A
- Revenue Growth
- TEI N/A
- FULC 2987.86
- 52 Week Low
- TEI $4.35
- FULC $2.86
- 52 Week High
- TEI $5.39
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- TEI 48.67
- FULC 41.64
- Support Level
- TEI $5.08
- FULC $3.93
- Resistance Level
- TEI $5.29
- FULC $5.17
- Average True Range (ATR)
- TEI 0.07
- FULC 0.30
- MACD
- TEI 0.02
- FULC -0.13
- Stochastic Oscillator
- TEI 66.67
- FULC 3.97
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments and Money Market Funds.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.